Business Wire

H3-DYNAMICS

23.11.2022 07:01:43 CET | Business Wire | Press release

Share
H3 Dynamics Completes World’s First Flight With Proprietary Distributed Hydrogen-Electric Nacelle Technology

The future of hydrogen aviation powered by H3 Dynamics’ distributed hydrogen propulsion nacelles has taken flight for the very first time in France.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121006001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

H3 Dynamics distributed hydrogen electric nacelles proven on first flight (Photo: Business Wire)

Following the announcement of its hydrogen aviation concept back in 2018, H3 Dynamics managed to become a topic at an Oval Office press conference on the very next day, and started what is now a global hydrogen aviation movement.

In November 2021, H3 Dynamics completed its first working hydrogen propulsion nacelle prototype. In July 2022, the first distributed pod system took to the skies on a scaled-down aircraft at “Hub Drones - Systematic” airfield near Paris. The hydrogen flight received clearance from the French civil air authorities (DGAC).

H3 Dynamics’ self-contained nacelle approach addresses technical, safety and cost challenges hydrogen aircraft developers could face at some point in the future. It achieves this by placing hydrogen and smaller fuel cells across a series of collaborative propulsion nacelles under the wings. A new 2022 study forecasts the global thrust nacelle market to reach $7 Billion by 2030 highlights H3 Dynamics’ hydrogen solution as a key new opportunity in the sector.

Other, higher-visibility hydrogen aircraft proponents will fly larger size aircraft much sooner – but they will do so by converting existing aircraft using fuel cells sourced from the automotive world – and storing large amounts of gas or liquid hydrogen inside the main fuselage.

“Not only is safety our first priority, but we don’t want hydrogen competing for revenue-generating airfreight and passenger space,” said Taras Wankewycz, Founder/CEO of H3 Dynamics. Distributing small systems solves technical headaches, such as thermal management, and increases safety through multiple redundancy.

H3 Dynamics’ 25kg test aircraft is already a breakthrough - with an electric flight range of up to 900km on liquid hydrogen, or 350km with pressurized hydrogen. Its externalized nacelle design also frees up 30L of fuselage volume with no hydrogen nor any powertrain elements inside. H3 Dynamics’ hydrogen propulsion nacelles could potentially become a “snap-on” retrofit for battery-powered unmanned eVTOL or fixed wing cargo drones.

Preparing for the arrival of much longer duration unmanned hydrogen flights - H3 Dynamics started to work on airspace safety with world-leading air traffic control companies. It has been building experience with high-volume enterprise data services being deployed in smart cities such as Singapore, and gradually coupling these with drone-agnostic charging stations.

By starting at the lower-end boundary of regulatory and certification efforts, H3 Dynamics doesn’t need to wait until 2035 to begin its commercial journey. “We all need to learn today with small commercial applications and gradually increase aircraft size over time together with all stakeholders – most importantly, the regulators.”

Now H3 Dynamics is already preparing its next steps.

It is exploring liquid hydrogen integration as part of a joint-development with ISAE-SUPAERO in Toulouse launched in 2019. The objective is a historical and symbolic Atlantic crossing on hydrogen electric propulsion in the coming two years.

And with airfield experiments feeding its digital twin capability for hydrogen aircraft design, H3 Dynamics is now working on a next generation platform powered by 6 independent hydrogen-electric nacelle systems. The aircraft will feature fast-refueling and will be used as a test bed for H3 Dynamics hydrogen-electric propulsion technology moving forward.

About H3 Dynamics: www.h3dynamics.com

H3 Dynamics is on a long-term mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. While the commercial opportunities around passenger-scale hydrogen aviation continue to mature, the company is implementing an incremental product and services roadmap that solves safety, technical, regulatory challenges starting small and simple, adding scale and complexity over time. The company currently has 95 employees and serves clients globally from its 3 regional headquarters in Toulouse, Austin and Singapore. H3 Dynamics is member of the Alliance for Zero Emission Aviation under the European Commission, the Lufthansa Cleantech Hub, Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221121006001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye